US 11,697,850 B2
Polymorphism in the Apo(a) gene predict responsiveness to acetylsalicylic acid treatment
Paul M. Ridker, Chestnut Hill, MA (US); Daniel Chasman, Cambridge, MA (US); and Dov Shiffman, Palo Alto, CA (US)
Assigned to The Brigham and Women's Hospital, Inc., Boston, MA (US); and Celera Corporation, Alameda, CA (US)
Filed by Celera Corporation, Alameda, CA (US); and The Brigham and Women's Hospital, Inc., Boston, MA (US)
Filed on Dec. 16, 2019, as Appl. No. 16/716,193.
Application 16/716,193 is a continuation of application No. 15/477,206, filed on Apr. 3, 2017, granted, now 10,550,433.
Application 15/477,206 is a continuation of application No. 14/534,516, filed on Nov. 6, 2014, abandoned.
Application 14/534,516 is a continuation of application No. 13/741,750, filed on Jan. 15, 2013, abandoned.
Application 13/741,750 is a continuation of application No. 13/090,116, filed on Apr. 19, 2011, abandoned.
Application 13/090,116 is a continuation of application No. 12/118,060, filed on May 9, 2008, granted, now 7,943,317.
Claims priority of provisional application 60/916,858, filed on May 9, 2007.
Prior Publication US 2020/0248262 A1, Aug. 6, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07H 21/04 (2006.01); C12Q 1/68 (2018.01); C12Q 1/6883 (2018.01); G01N 33/92 (2006.01); A61K 31/616 (2006.01); C12Q 1/6876 (2018.01)
CPC C12Q 1/6883 (2013.01) [A61K 31/616 (2013.01); C12Q 1/6876 (2013.01); G01N 33/92 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/172 (2013.01); G01N 2333/775 (2013.01); G01N 2500/04 (2013.01); G01N 2800/32 (2013.01); G01N 2800/50 (2013.01); G01N 2800/52 (2013.01)] 16 Claims
 
1. A method comprising:
(a) determining the identity of a single nucleotide polymorphism at position chromosome 6:160880877 (March 2006 assembly—NCBI build 36.1; rs3798220 dbSNP @ NCBI) of an apolipoprotein(a) (Apo(a)) gene in a human subject,
wherein the presence of cytosine or guanine at position chromosome 6:160880877 indicates responsiveness to acetylsalicylic acid,
wherein the presence of thymine or adenine at position chromosome 6:160880877 indicates non-responsiveness to acetylsalicylic acid; and
(b) administering acetylsalicylic acid to a human subject responsive to acetylsalicylic acid to reduce the risk of a cardiovascular event, or
administering an antiplatelet or antithrombotic agent that is not acetylsalicylic acid to a human subject non-responsive to acetylsalicylic acid to reduce the risk of a cardiovascular event.